Prediction of noncovalent drug/DNA interaction using computational docking models: Studies with over 1350 launched drugs

Environmental and Molecular Mutagenesis

Volumn 54, Issue 8, 2013, Pages 668-681

  Snyder, Ronald D ^a   Holt, Patrick A ^b   Maguire, Jon M ^b   Trent, John O ^b  

^a not available   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Computational docking; DNA intercalation; Noncovalent; Topoisomerase

Indexed keywords

ACEBUTOLOL; ACLARUBICIN; ACRIVASTINE; ADAPALENE; ALFUZOSIN; ALMOTRIPTAN; ALOSETRON; AMRUBICIN; AMSACRINE; ANTHRACYCLINE; ARBIDOL; ARBUTAMINE; ARGATROBAN; ARIPIPRAZOLE; ATOMOXETINE; AZASETRON; AZATADINE; AZELASTINE; BAMBUTEROL; BLEOMYCIN; DACTINOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ECHINOMYCIN; IDARUBICIN; INTERCALATING AGENT; MENOGARIL; MEPIRODIPINE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NOGALAMYCIN; UNINDEXED DRUG;

ARTICLE; DNA BINDING; DNA SEQUENCE; DRUG DNA INTERACTION; DRUG INDUSTRY; GENOTOXICITY; HYDROGEN BOND; MOLECULAR DOCKING; PREDICTION; STRUCTURE ACTIVITY RELATION;

EID: 84885855544     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21796     Document Type: Article

References (34)

1. Ashby, J. 1985. Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. Environ Mutagen 7:919-922.
2. Bal C, Baldeyrou B, Moz F, Lansieux L, Colson P, Kraus-Berthier L, Leonce S, Pierre A, Boussard M-F, Roussaue A, Wierzbicki M, Bailly C. 2004. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II. Biochem Pharmacol 68:1911-1922.
3. Dassonville L, Bailly C. 1999. Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone. Biochem Pharmacol 58:1307-1312.
4. Ferguson LR, Denny WA. 2007. Genotoxicity of non-covalent interactions: DNA intercalators. Mutat Res 623:14-23.
5. Hendry LB, Mahesh VB, Bransome JrED, Ewing DE. 2007. Small molecule intercalation with double stranded DNA: Implications for normal gene regulation and for predicting the biological efficacy and genotoxicity of drugs and other chemicals. Mutat Res 623:53-71.
6. Hoffmann GR, Laterza AM, Sylvia KE, Tartaglione JP. 2011. Potentiation of the mutagenicity and recombinagenicity of bleomycin in yeast by unconventional intercalating agents. Environ Mol Mutagen 52:130-144.
7. Holt PA, Chaires JB, Trent JO. 2008. Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex. J Chem Inf Model 48:1606-1615.
8. LeMee S, Pierre A, Markovits J, Atassi G, Jacquemin-Sablon A, Saucier J-M. 1998. S-16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Molec Pharmacol 53:213-220.
9. Nelson SM, Ferguson LR, Denny WA. 2007. Non-covalent ligand/DNA interactions: Minor groove binding agents. Mutat Res 623:24-40.
10. Oksuzoglu E, Tekiner-Gulbas B, Alper S, Temiz-Arpaci O, Ertan T, Yildiz I, Diril N, Sener-AkI E, Yalcion I. 2008. Some benzoxazoles and benzimidaziles as DNA topoisomerase I and II inhibitors. J Enz Inhib Med Chem 23:37-42.
11. Saravana KR, Moorthy SHN, Trivedi P. 2003. QSAR studies and molecular shape analysis of azonafide derivatives as topoisomerase II inhibitors. Indian J Pharm Sci 65:346-350.
12. Sato T, Matsuo Y, Honma T, Yokoyama S. 2008. In silico functional profiling of small molecules and its applications. J Med Chem 51:7705-7716.
13. Snyder RD. 1998. A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. Mutat Res 411:235-248.
14. Snyder RD. 2000. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen 35:13-21.
15. Snyder RD. 2007. Assessment of atypical DNA intercalating agents in biological and in silico systems. Mutat Res 623:72-82.
16. Snyder RD. 2009. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity. Environ Mol Mutagen 50:435-450.
17. Snyder RD. 2010. Possible structural and functional determinants contributing to the clastogenicity of pharmaceuticals. Environ Molec Mutagen 51:800-814.
18. Snyder RD, Arnone MR. 2002. Putative identification of functional interactions between DNA intercalating agents and topooisomerase II using the V79 in vitro micronucleus assay. Mutat Res 503 231-35.
19. Snyder RD, Brown JE. 2002. Evidence for and role of the dimethylamino group in tamoxifen DNA intercalation in intact Chinese hamster V79 cells. Drug Chem Toxicol 25:473-479.
20. Snyder RD, Diehl MS. 2000. The bleomycin amplification assay in V79 cells predicts frameshift mutagenicity of intercalating agents. Mutagen 15:203-205.
21. Snyder RD, Ewing D, Hendry LB. 2006. DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat Res 609:47-59.
22. Snyder RD, Ewing DE, Hendry LB. 2004. Evaluation of DNA intercalative potential of pharmaceuticals and other chemicals by cell-based and three-dimensional computational approaches. Environ Mol Mutagen 44:163-173.
23. Snyder RD, GIllies PJ. 2002. Evaluation of the clastogenic, DNA intercalative and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ Mol Mutagen 40:266-276.
24. Snyder RD, Green JW. 2001. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 488:151-169.
25. Snyder RD, Hendry LB. 2005. Toward a greater appreciation of non-covalent chemical/DNA interactions: Application of biological and computational approaches. Environ Mol Mutagen 45:100-105.
26. Snyder RD, McNulty J, Zairov G, Ewing DE, Hendry LB. 2005. The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. Mutat Res 578:88-99.
27. Snyder RD, Pearl GS, Mandakas G, Choy W-N, Goodsaid F, Rosenblum IY. 2004. Assessment of the sensitivity of the computational programs DEREK, TOPKAT and MCASE in prediction of the genotoxicity of pharmaceutical molecules. Environ Mol Mutagen 43:143-158.
28. Snyder RD, Strekowski L. 1999. Enhancement of bleomycin induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA binding compounds. Mutat Res 444:181-192.
29. Stojkovic MR, Marjanovic M, Pawlica D, Dudek L, Eilmes J, Kralj M, Piantinida I. 2010. Cationic side-chains control DNA/RNA binding properties and antiproliferative activity of dicationic dibenzotetraaza[14]annulene derivatives. New J Chem 34:500-507.
30. Strekowski L, Mokrosz JL, Tanious FA, Watson RA, Harden D, Mokrosz M, Edwards WD, Wilson WD. 1988. Molecular basis for bleomycin amplification: conformational and stereoelectronic effects in unfused amplifiers. J Med Chem 31:1231-1240.
31. Strekowski L, Strekowska A, Watson RA, Tanious FA, Nguyen LT, Wilson WD. 1987. Amplification of bleomycin-mediated degradation of DNA. J Med Chem 30:1415-1420.
32. Strekowski L, Wilson B. 2007. Noncovalent interactions with DNA: An overview. Mutat Res 623:3-13.
33. Wang S, Miller W, Milton J, Viocker N, Stewart A, Charlton P, MIstry P, Hardick D, Denny WA. 2002. Structure-activity relationships for analogues of the phenazine-based dual topoisomerase I/II inhibitor XR11576. Biorg Med Chem Lett 12:415-418.
34. Yamashita Y, Kawada S-Z, Nakano H. 1990. Induction of mammalian topoisomerase II dependent DNA cleavage by non-intercalative flavonoids, genistein and orobol. Biochem Pharmacol 39:737-744.